drugset

drugset / Trial / NCT00743652

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652 ↗

Phase 3 Completed 373 enrolled Pfizer

Non-randomizedParallel-groupOpen-labelPrevention

Summary

This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal conjugate vaccine in Alaskan Native Children.

Timeline

Start: 2009-01
Primary completion: 2010-09
Completion: 2010-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Prevnar 13	Vaccine	0.5 ml	Intramuscular

Indications